Topical treatments with certain prostaglandins (PGs), including FP receptor agonists, lower
intraocular pressure by increasing uveoscleral outflow. Although the precise mechanism for …

Latanoprost, used clinically in the treatment of glaucoma, induces growth of lashes and
ancillary hairs around the eyelids. Manifestations include greater thickness and length of …

Purpose To compare the diurnal intraocular pressure (IOP)-lowering effect of latanoprostene
bunod (LBN) ophthalmic solution 0.024% every evening (q pm) with timolol maleate 0.5 …

Purpose To compare the intraocular pressure (IOP)-lowering effect of latanoprostene bunod
(LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or …

Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. All
treatments, whether surgical or pharmaceutical, are aimed at lowering IOP. Prostaglandin …

The research that led to the concept of using prostaglandins for reduction of intraocular
pressure (IOP) has been discussed by Bito and goes back to the early 1980s, when it was …

Background Topical prostaglandin F 2α isopropyl ester increases uveoscleral outflow in
monkeys and humans. Objective To investigate the effects of prostaglandin F 2α isopropyl …

Anatomy and physiology 183 Examination of the conjunctiva 184 Diseases of the
conjunctiva: conjunctivitis 185 Trauma-associated conditions 200 Miscellaneous …

Glaucoma is the main cause of irreversible visual loss worldwide, and comprises a group of
progressive, age-related, and chronic optic neuropathies. Prostaglandin analogs are …

Intraocular pressure reduction is the only available and evidence-based medical therapy for
glaucoma. Currently, the first-line eye drops are prostaglandin analogues including …